Aditya Patel
YOU?
Author Swipe
View article: Identification of a BACH1 lung cancer signature: A novel tool for understanding BACH1 biology and identifying new inhibitors
Identification of a BACH1 lung cancer signature: A novel tool for understanding BACH1 biology and identifying new inhibitors Open
BACH1 is a transcriptional repressor that regulates oxidative stress and inflammatory responses and has emerged as a promising therapeutic target in cancer and other diseases. In lung cancer, BACH1 overexpression is linked to poor prognosi…
View article: Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis Open
Background and Aims Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis of inflammatory bowel disease. Deucravacitinib is a novel, oral, selective, allosteric tyros…
View article: A randomized, double-blind, placebo-controlled phase 2b trial using the novel predictive genetic biomarker DGM4 for liafensine in treatment-resistant depression
A randomized, double-blind, placebo-controlled phase 2b trial using the novel predictive genetic biomarker DGM4 for liafensine in treatment-resistant depression Open
Prior clinical trials evaluating liafensine for treatment-resistant depression (TRD) in unselected patients did not demonstrate benefit vs controls. A novel pharmacogenomic biomarker, DGM4, was discovered as a predictor of liafensine’s eff…
View article: The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever
The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever Open
These studies demonstrate that INO-4500 can provide short- and long-term protection in NHPs from lethal LASV challenge.
View article: Left atrial septal pouch thrombus: An unusual cause of an embolic stroke
Left atrial septal pouch thrombus: An unusual cause of an embolic stroke Open
Key Clinical Message Left‐atrial septal pouch (LASP) is a newly described anatomical variant caused by incomplete fusion of the septa primum and secundum. This case visualizes LASP as a potential nidus for blood stasis and cardiac embolism…
View article: Left Atrial Septal Pouch Thrombus: An Unusual Cause of An Embolic Stroke
Left Atrial Septal Pouch Thrombus: An Unusual Cause of An Embolic Stroke Open
A large proportion of ischemic strokes have an undetermined cause and are considered “cryptogenic.” A left atrial septal pouch (LASP) develops due to incomplete fusion of the septa primum and secundum, forming a pocket at the interatrial s…
View article: P052 Mucosal IgG-like naive B-cell expansion and maturation contribute to ulcerative colitis pathogenesis
P052 Mucosal IgG-like naive B-cell expansion and maturation contribute to ulcerative colitis pathogenesis Open
Background A higher abundance of colonic naive B-cells and IgG plasma cells is implicated in the pathogenesis of ulcerative colitis (UC) during active inflammatory episodes. However, B-cell inhibition by targeting CD20 was found to be inef…
View article: DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study
DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study Open
Background Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates the signalling of key cytokines involved in ulcerative colitis (UC) pathophysiology. Deucravacitinib (DEUC) is a novel, oral, selective TYK2 inhibitor that binds …
View article: P402 Incidence and outcomes of herpes zoster in the ozanimod phase, 3 ulcerative colitis and relapsing multiple sclerosis clinical program
P402 Incidence and outcomes of herpes zoster in the ozanimod phase, 3 ulcerative colitis and relapsing multiple sclerosis clinical program Open
Background Patients with ulcerative colitis (UC) and patients with multiple sclerosis (MS) have an elevated risk of developing herpes zoster (HZ), caused by reactivation of latent varicella zoster virus (VZV). Increased incidence of HZ has…
View article: Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors Open
At clinically relevant doses and exposures, deucravacitinib demonstrates highly selective inhibition of TYK2 and not JAK 1/2/3. Tofacitinib, upadacitinib, and baricitinib variably inhibit JAK 1/2/3 but not TYK2. These results indicate that…
View article: Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors
Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors Open
not available.